Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IOBT
stocks logo

IOBT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.190
-58.24%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for IO Biotech, Inc. (IOBT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -65.23%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.19%
In Past 3 Month
Stock Price
Go Down
down Image
-65.23%
In Past 3 Month
Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 1.70 USD with a low forecast of 0.39 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 1.70 USD with a low forecast of 0.39 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 0.678
sliders
Low
0.39
Averages
1.70
High
3.00
Current: 0.678
sliders
Low
0.39
Averages
1.70
High
3.00
Piper Sandler
Overweight
downgrade
$10 -> $3
2025-10-22
Reason
Piper Sandler
Price Target
$10 -> $3
2025-10-22
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on IO Biotech to $3 from $10 and keeps an Overweight rating on the shares following several updates, including recent disclosure of FDA's recommendation to not submit a BLA based on data from the pivotal study of Cylembio + pembrolizumab in 1L advanced melanoma. IO now intends to align with FDA on design of a potential new registrational study for Cylembio and still plans to discuss the data with EU regulators. Based on this news, the firm is pushing back U.S. launch in advanced melanoma to FY29.
TD Cowen
TD Cowen
Buy
to
Hold
downgrade
2025-09-30
Reason
TD Cowen
TD Cowen
Price Target
2025-09-30
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded IO Biotech to Hold from Buy without a price target after the FDA recommended the company not file an application for Cylembio plus pembrolizumab in melanoma. IO is reducing its workforce by 50% but the company's cash "is tight" at $38M into Q1 of 2026, the analyst tells investors in a research note. TD cites IO's lack of late-stage catalysts for the downgrade.
Morgan Stanley
Overweight -> Equal Weight
downgrade
$4
2025-09-30
Reason
Morgan Stanley
Price Target
$4
2025-09-30
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded IO Biotech to Equal Weight from Overweight with a price target of 39c, down from $4, after the company announced following a pre-BLA meeting with the FDA that regulators recommended that IO Biotech not submit a BLA based on data from the Phase 3 IOB-013 clinical trial. While the firm continues to believe Cylembio has potential, the FDA requiring another Phase 3 study, combined with limited cash, increases near-term uncertainty, the analyst tells investors.
H.C. Wainwright
Emily Bodnar
Buy
to
Neutral
downgrade
2025-09-29
Reason
H.C. Wainwright
Emily Bodnar
Price Target
2025-09-29
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Emily Bodnar downgraded IO Biotech to Neutral from Buy with no price target.
H.C. Wainwright
analyst
Buy -> Neutral
downgrade
2025-09-29
Reason
H.C. Wainwright
analyst
Price Target
2025-09-29
downgrade
Buy -> Neutral
Reason
As previously reported, H.C. Wainwright downgraded IO Biotech to Neutral from Buy with no price target after the company gave an update from its pre-BLA meeting with the FDA and reported that the agency does not recommend that the company submit a BLA for Cylembio. Given the company's cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new Phase 3 trial, says the analyst, who downgrades the shares based on the shift from a near-term regulatory review to planning a new large pivotal trial.
H.C. Wainwright
Buy
maintain
$12 -> $14
2025-05-14
Reason
H.C. Wainwright
Price Target
$12 -> $14
2025-05-14
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on IO Biotech to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses for the target increase. The analyst says IO's Phase 3 advanced melanoma data is on track for Q3.
See All Ratings

Valuation Metrics

The current forward P/E ratio for IO Biotech Inc (IOBT.O) is -1.20, compared to its 5-year average forward P/E of -1.41. For a more detailed relative valuation and DCF analysis to assess IO Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.41
Current PE
-1.20
Overvalued PE
-0.56
Undervalued PE
-2.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.04
Undervalued EV/EBITDA
-1.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IOBT News & Events

Events Timeline

(ET)
2025-11-14
08:08:51
IO Biotech announces Q3 earnings per share of (13c), compared to (36c) in the previous year.
select
2025-11-07 (ET)
2025-11-07
09:13:55
IO Biotech Reveals Pre-Clinical Findings for IO112 and IO170
select
2025-10-20 (ET)
2025-10-20
05:29:12
IO Biotech announces enhanced results from Cylembio
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-27Newsfilter
IO Biotech to Showcase Cancer Vaccine Progress at Two Major Healthcare Conferences
  • Conference Participation: IO Biotech will participate in the 8th Annual Evercore Healthcare Conference in Florida on December 2, 2025, and the Piper Sandler Annual Healthcare Conference in New York on December 3, 2025, showcasing its latest advancements in cancer vaccines to attract investor interest and enhance market confidence.
  • Executive Attendance: CEO Mai-Britt Zocca, PhD, and CFO Amy Sullivan will engage in fireside chats and one-on-one meetings with investors at each conference, further elevating the company's visibility and credibility among stakeholders.
  • Webcast Availability: The fireside chats will be accessible via webcast, allowing investors to tune in through the
[object Object]
Preview
1.0
11-27Globenewswire
IO Biotech to Participate in Two Major Healthcare Conferences Showcasing Cancer Vaccine Progress
  • Conference Participation: IO Biotech will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Florida, showcasing its cancer vaccine development progress, which is expected to attract investor interest and enhance the company's visibility.
  • Executive Attendance: CEO Mai-Britt Zocca, PhD, and CFO Amy Sullivan will engage in one-on-one meetings with investors at both conferences, aiming to strengthen relationships with potential investors and drive funding opportunities.
  • Webcast Availability: The fireside chats will be accessible via webcast, allowing investors to view the discussions on IO Biotech's website under the “News and Events” section, which is anticipated to improve company transparency and bolster investor confidence.
  • Product Showcase: IO Biotech will present its cancer vaccine candidate Cylembio®, based on the T-win® platform, which will help raise market awareness of its innovative therapies and potentially facilitate future funding for clinical trials.
[object Object]
Preview
9.0
11-20Globenewswire
Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated

  • Fair-Value Remeasurement Importance: Fair-value remeasurements under U.S. GAAP are becoming essential for late-stage biotech companies, providing insights into the financial implications of scientific advancements and enhancing shareholder value.

  • Oncotelic's Valuation Milestone: Oncotelic Therapeutics is set to undergo a significant fair-value remeasurement of its 45% stake in GMP Bio, with a new valuation indicating a potential asset value of approximately $765 million, reflecting progress in its oncology-focused pipeline.

  • Advancements in Clinical Programs: Oncotelic's pipeline includes multiple late-stage oncology and rare disease programs, with significant milestones achieved, such as advancements in OT-101 for pancreatic cancer and other promising candidates targeting various conditions.

  • Nanomedicine Market Growth: The valuation of Oncotelic's Deciparticle nanomedicine platform is tied to the growing market for nanomedicine, projected to exceed $350 billion by 2032, highlighting the potential for substantial financial recognition as clinical developments progress.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IO Biotech Inc (IOBT) stock price today?

The current price of IOBT is 0.6781 USD — it has increased 5.77 % in the last trading day.

arrow icon

What is IO Biotech Inc (IOBT)'s business?

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

arrow icon

What is the price predicton of IOBT Stock?

Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 1.70 USD with a low forecast of 0.39 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IO Biotech Inc (IOBT)'s revenue for the last quarter?

IO Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is IO Biotech Inc (IOBT)'s earnings per share (EPS) for the last quarter?

IO Biotech Inc. EPS for the last quarter amounts to -0.13 USD, decreased -63.89 % YoY.

arrow icon

What changes have occurred in the market's expectations for IO Biotech Inc (IOBT)'s fundamentals?

The market is revising No Change the revenue expectations for IO Biotech, Inc. (IOBT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -65.23%.
arrow icon

How many employees does IO Biotech Inc (IOBT). have?

IO Biotech Inc (IOBT) has 80 emplpoyees as of December 05 2025.

arrow icon

What is IO Biotech Inc (IOBT) market cap?

Today IOBT has the market capitalization of 48.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free